Some KCs work well in specific disease families: complexes in ciliopathies (Wilcoxon signed-rank test, WST, p-value < 0.001), drug sharing in tumor syndromes (WST, p-value < 0.001), or co-essentiality in metabolic disorders (WST, p-value  < 0.001) (Figure 2A and Figure S4). This evidence concerns the gene TBCE and metabolic disease.